{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T03:36:59Z","timestamp":1789270619657,"version":"build-2803163510"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","jocn-journal.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.jocn.2024.110774","type":"journal-article","created":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T21:12:20Z","timestamp":1723324340000},"page":"110774","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Innovative solutions? Belzutifan therapy for hemangioblastomas in Von Hippel-Lindau disease: A systematic review and single-arm meta-analysis"],"prefix":"10.1016","volume":"128","author":[{"given":"Lucca B.","family":"Palavani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Camerotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardo","family":"Vieira Nogueira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1rcio Yuri","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo B.","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"Pari Mitre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilson","family":"Coelho Nogueira de Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gisele L\u00facia","family":"Canto Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis F.","family":"Fabrini Paleare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e1vio","family":"Batista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filipi","family":"Fim Andre\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Bertani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Dias Polverini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"283","key":"10.1016\/j.jocn.2024.110774_b0005","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1093\/qjmed\/77.2.1151","article-title":"Clinical features and natural history of von Hippel-Lindau disease","volume":"77","author":"Maher","year":"1990","journal-title":"Q J Med"},{"issue":"6","key":"10.1016\/j.jocn.2024.110774_b0010","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/ejhg.2010.175","article-title":"von Hippel-Lindau disease: a clinical and scientific review","volume":"19","author":"Maher","year":"2011","journal-title":"Eur J Hum Genet"},{"issue":"10","key":"10.1016\/j.jocn.2024.110774_b0015","first-page":"999","article-title":"Peripheral nerve hemangioblastoma","volume":"11","author":"Giannini","year":"1998","journal-title":"Mod Pathol"},{"issue":"13","key":"10.1016\/j.jocn.2024.110774_b0020","doi-asserted-by":"crossref","first-page":"358","DOI":"10.25259\/SNI_304_2022","article-title":"Aggressive dissemination of central nervous system hemangioblastoma without association with von Hippel-Lindau disease: A case report and literature review","volume":"12","author":"Dantas","year":"2022","journal-title":"Surg Neurol Int"},{"issue":"4","key":"10.1016\/j.jocn.2024.110774_b0025","doi-asserted-by":"crossref","first-page":"971","DOI":"10.3171\/2015.4.JNS1533","article-title":"Biological and clinical impact of hemangioblastoma-associated peritumoral cysts in von Hippel-Lindau disease","volume":"124","author":"Huntoon","year":"2016","journal-title":"J Neurosurg."},{"issue":"2","key":"10.1016\/j.jocn.2024.110774_b0030","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1148\/radiol.2019182646","article-title":"Bosniak classification of cystic renal masses, version 2019: An update proposal and needs assessment","volume":"292","author":"Silverman","year":"2019","journal-title":"Radiology"},{"issue":"13","key":"10.1016\/j.jocn.2024.110774_b0035","doi-asserted-by":"crossref","first-page":"5669","DOI":"10.2147\/OTT.S190753","article-title":"Von Hippel-Lindau disease: current challenges and future prospects","volume":"16","author":"Gl\u00e4sker","year":"2020","journal-title":"Onco Targets Ther"},{"issue":"2","key":"10.1016\/j.jocn.2024.110774_b0040","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s11060-022-04021-8","article-title":"Presentation, imaging, patterns of care, growth, and outcome in sporadic and von Hippel-Lindau-associated central nervous system hemangioblastomas","volume":"159","author":"Takami","year":"2022","journal-title":"J Neurooncol"},{"issue":"5","key":"10.1016\/j.jocn.2024.110774_b0045","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.3171\/2014.1.JNS131431","article-title":"Prospective natural history study of central nervous system hemangioblastomas in von Hippel-Lindau disease","volume":"120","author":"Lonser","year":"2014","journal-title":"J Neurosurg"},{"issue":"11","key":"10.1016\/j.jocn.2024.110774_b0050","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1001\/jama.300.11.1334","article-title":"Neurologic manifestations of von Hippel-Lindau disease","volume":"300","author":"Butman","year":"2008","journal-title":"JAMA"},{"issue":"22","key":"10.1016\/j.jocn.2024.110774_b0055","doi-asserted-by":"crossref","first-page":"5492","DOI":"10.3390\/cancers14225492","article-title":"Sporadic and von Hippel-Lindau related hemangioblastomas of brain and spinal cord: multimodal imaging for intraoperative strategy","volume":"14","author":"Mazzapicchi","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jocn.2024.110774_b0060","first-page":"1","article-title":"Minimally invasive resection of spinal hemangioblastoma: feasibility and clinical results in a series of 18 patients","volume":"9","author":"Kr\u00fcger","year":"2019","journal-title":"J Neurosurg Spine"},{"issue":"1","key":"10.1016\/j.jocn.2024.110774_b0065","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11060-017-2697-0","article-title":"Stereotactic radiosurgery for central nervous system hemangioblastoma: systematic review and meta-analysis","volume":"137","author":"Pan","year":"2018","journal-title":"J Neurooncol"},{"issue":"1","key":"10.1016\/j.jocn.2024.110774_b0070","doi-asserted-by":"crossref","first-page":"E12","DOI":"10.3171\/2016.10.FOCUS16361","article-title":"Image-guided stereotactic radiosurgery for treatment of spinal hemangioblastoma","volume":"42","author":"Pan","year":"2017","journal-title":"Neurosurg Focus"},{"issue":"2","key":"10.1016\/j.jocn.2024.110774_b0075","first-page":"167","article-title":"Invasive management of renal cell carcinoma in von Hippel-Lindau disease","volume":"73","author":"Carrion","year":"2020","journal-title":"Cent European J Urol"},{"issue":"5","key":"10.1016\/j.jocn.2024.110774_b0080","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/s41591-021-01324-7","article-title":"Inhibition of hypoxia-inducible factor-2\u03b1 in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis","volume":"27","author":"Choueiri","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.jocn.2024.110774_b0085","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","article-title":"Belzutifan for renal cell carcinoma in von Hippel-Lindau disease","volume":"385","author":"Jonasch","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocn.2024.110774_b0090","unstructured":"LITESPARK-004 (MK-6482-004) phase 2 study of belzutifan, an oral hypoxia-inducible factor 2\u03b1 inhibitor (HIF-2\u03b1), for von Hippel-Lindau (VHL) disease: Update with more than two years of follow-up data. J Clin Oncol Published 2022. Accessed February 8, 2024. https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2022.40.16_suppl.4546."},{"issue":"Supplement_3","key":"10.1016\/j.jocn.2024.110774_b0095","article-title":"SYST-18 Belzutifan treatment for patients with von hippel-lindau disease\u2013associated central nervous system hemangioblastomas enrolled in the phase 2 litespark-004 study","volume":"5","author":"Narayan","year":"2023","journal-title":"Neuro-oncol Adv"},{"issue":"3","key":"10.1016\/j.jocn.2024.110774_b0100","article-title":"First clinical experience with belzutifan in von Hippel-Lindau disease associated CNS hemangioblastoma. CNS","volume":"11","author":"Dhawan","year":"2022","journal-title":"Oncol"},{"issue":"2","key":"10.1016\/j.jocn.2024.110774_b0105","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s11060-023-04496-z","article-title":"The outcome of central nervous system hemangioblastomas in Von Hippel-Lindau (VHL) disease treated with belzutifan: a single-institution retrospective experience","volume":"165","author":"Zamarud","year":"2023","journal-title":"J Neurooncol"},{"key":"10.1016\/j.jocn.2024.110774_b0110","doi-asserted-by":"crossref","unstructured":"Grimes JM, Gershkovich A, Bogomolny D, Marr BP. Two cases of von Hippel-Lindau syndrome-associated retinal hemangioblastoma treated with belzutifan. Retin Cases Brief Rep 2022 Nov 16. doi: 10.1097\/ICB.0000000000001376. Epub ahead of print. PMID: 36730578.","DOI":"10.1097\/ICB.0000000000001376"},{"key":"10.1016\/j.jocn.2024.110774_b0115","doi-asserted-by":"crossref","unstructured":"Successful combination of database search and snowballing for identification of primary studies in systematic literature studies. https:\/\/doi.org\/10.1016\/j.infsof.2022.106908.","DOI":"10.1016\/j.infsof.2022.106908"},{"key":"10.1016\/j.jocn.2024.110774_b0120","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"RECIST 1.1-update and clarification: From the RECIST committee","volume":"62","author":"Schwartz","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jocn.2024.110774_b0125","unstructured":"Experts Committee on Cancer -Related Anemia; Chinese Society of Clinical Oncology (CSCO). Clinical practice guidelines on cancer-related anemia (2012-2013 Edition). Chin Clin Oncol. 2012;1(2):18. doi:10.3978\/j.issn.2304-3865.2012.10.01."},{"key":"10.1016\/j.jocn.2024.110774_b0130","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.jocn.2024.110774_b0135","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1136\/bmjebm-2017-110853","article-title":"Methodological quality and synthesis of case series and case reports","volume":"23","author":"Murad","year":"2018","journal-title":"BMJ Evid Based Med"},{"key":"10.1016\/j.jocn.2024.110774_b0140","doi-asserted-by":"crossref","DOI":"10.1097\/ICB.0000000000001516","article-title":"Belzutifan for treatment of giant retinal hemangioblastoma with extrascleral extension associated with von Hippel-Lindau syndrome","author":"Cotton","year":"2023","journal-title":"Retinal Cases Brief Rep"},{"key":"10.1016\/j.jocn.2024.110774_b0145","article-title":"Belzutifan impact on VHL-associated CNS hemangioblastomas","volume":"165","author":"Demers","year":"2023","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.jocn.2024.110774_b0150","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s11912-019-0752-z","article-title":"HIF Inhibitors: status of current clinical development","volume":"21","author":"Fallah","year":"2019","journal-title":"Curr Oncol Rep."},{"key":"10.1016\/j.jocn.2024.110774_b0155","doi-asserted-by":"crossref","unstructured":"Iliopoulos O, Rapalino O, Barker FG, et al. Belzutifan treatment of Von Hippel-Lindau (VHL) related central nervous system (CNS) hemangioblastomas (HBs): A single institution experience. Presented at: 2078 Poster Session; 2023. Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA.","DOI":"10.1200\/JCO.2023.41.16_suppl.2078"},{"issue":"15_suppl","key":"10.1016\/j.jocn.2024.110774_b0160","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1200\/JCO.2023.41.16_suppl.2008","article-title":"Belzutifan treatment for von Hippel-Lindau (VHL) disease\u2013associated central nervous system (CNS) hemangioblastomas (HBs) in the phase 2 LITESPARK-004 study","volume":"41","author":"Iliopoulos","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jocn.2024.110774_b0165","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s11060-023-04395-3","article-title":"Belzutifan in adults with VHL-associated central nervous system hemangioblastoma: a single-center experience","volume":"164","author":"Neth","year":"2023","journal-title":"J Neurooncol"},{"key":"10.1016\/j.jocn.2024.110774_b0170","article-title":"Oral HIF-2\u03b1 inhibitor belzutifan for ocular von Hippel-Lindau (VHL) disease","author":"Wiley","year":"2021","journal-title":"ARVO Annual Meeting Abstract"},{"issue":"2","key":"10.1016\/j.jocn.2024.110774_b0175","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1210\/endrev\/bnac025","article-title":"Hypoxia-Inducible factor 2 Alpha (HIF2\u03b1) inhibitors: targeting genetically driven tumor hypoxia","volume":"44","author":"Toledo","year":"2023","journal-title":"Endocr Rev"},{"issue":"22","key":"10.1016\/j.jocn.2024.110774_b0180","doi-asserted-by":"crossref","first-page":"4843","DOI":"10.1158\/1078-0432.CCR-22-1054","article-title":"FDA Approval summary: belzutifan for von Hippel-Lindau disease-associated tumors","volume":"28","author":"Fallah","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.jocn.2024.110774_b0185","first-page":"46","article-title":"Selective HIF2A inhibitors in the management of clear cell renal cancer and Von Hippel-Lindau-Disease-associated tumors","volume":"11","author":"Su\u00e1rez","year":"2023","journal-title":"Med Sci (Basel, Switzerland)"},{"issue":"1","key":"10.1016\/j.jocn.2024.110774_b0195","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3390\/medicina60010084","article-title":"Efficacy of hypoxia-inducible factor prolyl hydroxylase inhibitor on clinical parameters in patients with heart failure","volume":"60","author":"Yazaki","year":"2024","journal-title":"Medicina (Kaunas)"},{"issue":"6","key":"10.1016\/j.jocn.2024.110774_b0200","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1053\/j.ajkd.2016.12.011","article-title":"Hypoxia-inducible factor prolyl hydroxylase inhibitors: a potential new treatment for anemia in patients with CKD","volume":"69","author":"Gupta","year":"2017","journal-title":"Am J Kidney Dis."},{"issue":"4","key":"10.1016\/j.jocn.2024.110774_b0205","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/neup.12111","article-title":"Angiogenesis and expression of PDGF-C, VEGF, CD105 and HIF-1\u03b1 in human glioblastoma","volume":"34","author":"Clara","year":"2014","journal-title":"Neuropathology"},{"issue":"12","key":"10.1016\/j.jocn.2024.110774_b0210","first-page":"e32624","article-title":"Intra-arterial bevacizumab for posterior fossa hemangioblastoma","volume":"14","author":"Sokol","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.jocn.2024.110774_b0215","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s11060-020-03435-6","article-title":"Super selective intra-arterial cerebral infusion of modern chemotherapeutics after blood-brain barrier disruption: where are we now, and where we are going","volume":"147","author":"D'Amico","year":"2020","journal-title":"J. Neurooncol."},{"issue":"6","key":"10.1016\/j.jocn.2024.110774_b0220","doi-asserted-by":"crossref","DOI":"10.1177\/1010428317709637","article-title":"HIF-2\u03b1 not HIF-1\u03b1 overexpression confers poor prognosis in non-small cell lung cancer","volume":"39","author":"Gao","year":"2017","journal-title":"Tumour Biol"},{"key":"10.1016\/j.jocn.2024.110774_b0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103231","article-title":"The relationship between hypoxia-inducible factor 1\u03b1 (HIF-1\u03b1) and patient survival in breast cancer: Systematic review and meta-analysis","volume":"159","author":"Shamis","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"10.1016\/j.jocn.2024.110774_b0230","doi-asserted-by":"crossref","first-page":"37","DOI":"10.15586\/jkcvhl.2017.90","article-title":"Management strategies and outcomes for VHL-related craniospinal hemangioblastomas","volume":"4","author":"Ordookhanian","year":"2017","journal-title":"J kidney Cancer VHL"},{"issue":"3","key":"10.1016\/j.jocn.2024.110774_b0235","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ccr.2008.01.034","article-title":"HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion","volume":"13","author":"Du","year":"2008","journal-title":"Cancer Cell"},{"issue":"8","key":"10.1016\/j.jocn.2024.110774_b0240","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1080\/14728222.2023.2248381","article-title":"Targeting HIF-1 for prostate cancer: a synthesis of preclinical evidence","volume":"27","author":"Zohar","year":"2023","journal-title":"Expert Opin Ther Targets"},{"issue":"20","key":"10.1016\/j.jocn.2024.110774_b0245","doi-asserted-by":"crossref","first-page":"5585","DOI":"10.1158\/1078-0432.CCR-12-0858","article-title":"Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy","volume":"18","author":"Meijer","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jocn.2024.110774_b0250","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.2027","article-title":"Safety and activity of a first-in-class oral HIF2-alpha inhibitor, PT2385, in patients with first recurrent glioblastoma (GBM)","volume":"37","author":"Strowd","year":"2019","journal-title":"JCO"},{"issue":"1","key":"10.1016\/j.jocn.2024.110774_b0255","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3171\/jns.2003.98.1.0082","article-title":"The natural history of hemangioblastomas of the central nervous system in patients with von Hippel-Lindau disease","volume":"98","author":"Wanebo","year":"2003","journal-title":"J Neurosurg"},{"issue":"9","key":"10.1016\/j.jocn.2024.110774_b0260","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.3390\/genes12091414","article-title":"Investigation and management of apparently sporadic central nervous system haemangioblastoma for evidence of Von Hippel-Lindau Disease","volume":"12","author":"Furness","year":"2021","journal-title":"Genes (Basel)"},{"issue":"2","key":"10.1016\/j.jocn.2024.110774_b0265","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3171\/jns.2006.105.2.248","article-title":"Long-term natural history of hemangioblastomas in patients with von Hippel-Lindau disease: implications for treatment","volume":"105","author":"Ammerman","year":"2006","journal-title":"J Neurosurg"},{"key":"10.1016\/j.jocn.2024.110774_b0270","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jocn.2023.09.021","article-title":"Assessing the efficacy and safety of hemangioblastoma embolization: A comprehensive systematic review and meta-analysis","volume":"117","author":"Palavani","year":"2023","journal-title":"J Clin Neurosci."},{"issue":"3","key":"10.1016\/j.jocn.2024.110774_b0275","first-page":"502","article-title":"Preoperative embolization of brain and spinal hemangioblastomas","volume":"33","author":"Tampieri","year":"1993","journal-title":"Neurosurgery"},{"issue":"1","key":"10.1016\/j.jocn.2024.110774_b0280","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/neuonc\/nop018","article-title":"Prospective evaluation of radiosurgery for hemangioblastomas in von Hippel-Lindau disease","volume":"12","author":"Asthagiri","year":"2010","journal-title":"Neuro Oncol"},{"issue":"4","key":"10.1016\/j.jocn.2024.110774_b0285","doi-asserted-by":"crossref","first-page":"758","DOI":"10.3174\/ajnr.A1360","article-title":"Aggressive leptomeningeal hemangioblastomatosis of the central nervous system in a patient with von Hippel-Lindau disease","volume":"30","author":"Courcoutsakis","year":"2009","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1016\/j.jocn.2024.110774_b0290","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.570103","article-title":"Incidence, prognostic factors and survival for hemangioblastoma of the central nervous system: analysis based on the surveillance, epidemiology, and end results database","volume":"10","author":"Yin","year":"2020","journal-title":"Front Oncol."},{"issue":"4","key":"10.1016\/j.jocn.2024.110774_b0295","doi-asserted-by":"crossref","first-page":"A1585","DOI":"10.1016\/j.chest.2022.08.1332","article-title":"Belzutifan-induced hypersensitivity pneumonitis","volume":"162","author":"Fiscus","year":"2022","journal-title":"Chest"}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586824003138?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586824003138?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T15:18:07Z","timestamp":1725981487000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0967586824003138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":58,"alternative-id":["S0967586824003138"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2024.110774","relation":{},"ISSN":["0967-5868"],"issn-type":[{"value":"0967-5868","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Innovative solutions? Belzutifan therapy for hemangioblastomas in Von Hippel-Lindau disease: A systematic review and single-arm meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2024.110774","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"110774"}}